The Blue Box Biomedical Solutions Funding & Investors
Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecology clinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors.
thebluebox.aiTotal Amount Raised: $2,102,110
The Blue Box Biomedical Solutions Funding Rounds
Pre Seed
322,702 EUR
Grant
661,156 EUR
Seed
540,631 EUR
Seed Investors
Grow Venture PartnersUnconventional VenturesGrant
333,967 EUR
Pre Seed
156,330 EUR
Pre Seed
87,324 EUR
Funding info provided by Diffbot.